Evidence map›Paper›PMID 25844037›Full record

ArticleInternational journal of nanomedicine2015

Treating cancer stem cells and cancer metastasis using glucose-coated gold nanoparticles.

Chenxia Hu, Martin Niestroj, Daniel Yuan, Steven Chang, Jie Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Pharmaceutics · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2020
    Review
  18. Article
  19. Article
  20. Cancer stem cell impact on clinical oncology.World journal of stem cells · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Chenxia HuFaculty of Chinese Pharmaceutical Science, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Martin NiestrojCanadian Light Source, Saskatoon, SK, Canada ; Physics Department, Bonn University, Bonn, Germany.
Daniel YuanBiomedical Engineering Department, Johns Hopkins University, Baltimore, MD, USA.
Steven ChangFaculty of Engineering, University of Alberta, Edmonton, AB, Canada.
Jie ChenFaculty of Engineering, University of Alberta, Edmonton, AB, Canada ; Canadian National Research Council/National Institute for Nanotechnology, Edmonton, AB, Canada.
Johns Hopkins University · USUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer ranks among the leading causes of human mortality. Cancer becomes intractable when it spreads from the primary tumor site to various organs (such as bone, lung, liver, and then brain). Unlike solid tumor cells, cancer stem cells and metastatic cancer cells grow in a non-attached (suspension) form when moving from their source to other locations in the body. Due to the non-attached growth nature, metastasis is often first detected in the circulatory systems, for instance in a lymph node near the primary tumor. Cancer research over the past several decades has primarily focused on treating solid tumors, but targeted therapy to treat cancer stem cells and cancer metastasis has yet to be developed. Because cancers undergo faster metabolism and consume more glucose than normal cells, glucose was chosen in this study as a reagent to target cancer cells. In particular, by covalently binding gold nanoparticles (GNPs) with thio-PEG (polyethylene glycol) and thio-glucose, the resulting functionalized GNPs (Glu-GNPs) were created for targeted treatment of cancer metastasis and cancer stem cells. Suspension cancer cell THP-1 (human monocytic cell line derived from acute monocytic leukemia patients) was selected because it has properties similar to cancer stem cells and has been used as a metastatic cancer cell model for in vitro studies. To take advantage of cancer cells' elevated glucose consumption over normal cells, different starvation periods were screened in order to achieve optimal treatment effects. Cancer cells were then fed using Glu-GNPs followed by X-ray irradiation treatment. For comparison, solid tumor MCF-7 cells (breast cancer cell line) were studied as well. Our irradiation experimental results show that Glu-GNPs are better irradiation sensitizers to treat THP-1 cells than MCF-7 cells, or Glu-GNPs enhance the cancer killing of THP-1 cells 20% more than X-ray irradiation alone and GNP treatment alone. This finding can help oncologists to design therapeutic strategies to target cancer stem cells and cancer metastasis.

Indexed as

Metal NanoparticlesAntineoplastic AgentsCell Line, TumorFemaleGlucoseGoldHumansMCF-7 CellsNeoplastic Stem CellsPolyethylene GlycolsX-RaysAntineoplastic AgentsGlucoseGoldPolyethylene Glycolscancer metastasiscancer stem cellsglucose capped gold nanoparticlesirradiation therapysuspension cancer cellstargeted treatment

Identifiers

PMID25844037
PMCPMC4368028
OpenAlexW2080100501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.